RT Journal Article
T1 Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort.
A1 Garrido-Torres, Nathalia
A1 Ruiz-Veguilla, Miguel
A1 Alameda, Luis
A1 Canal-Rivero, Manuel
A1 Ruiz, María Juncal
A1 Gómez-Revuelta, Marcos
A1 Ayesa-Arriola, Rosa
A1 Rubio-García, Ana
A1 Crespo-Facorro, Benedicto
A1 Vázquez-Bourgon, Javier
K1 Drug-naïve
K1 Metabolic
K1 Schizophrenia
K1 Syndrome
AB Few investigations have been carried out on metabolic syndrome in antipsychotic- naïve patients with schizophrenia. Our primary objective was to compare the prevalence of Metabolic Syndrome (MetS), as defined by the National Cholesterol Education Program, Adult Treatment Panel III in 2001 (NCEP-ATP III), between a Spanish cohort of 303 drug-naïve patients with a first episode of psychosis (FEP) without any previous cardiovascular condition, and 153 healthy individuals. Participants included 303 patients with FEP (M:F 53:46) and 153 control subjects (M:F 56:43). The mean and standard deviation ages were 31(9.38) and 29 (7.57) years in the study and control groups respectively (F = 4.09; p = 0.93). We found that the prevalence of MetS in drug-naïve patients with FEP (5.6 %) was similar to the prevalence of MetS in age-sex matched controls (5.12 %). However, 60.7 % of patients with FEP met at least one of the five MetS components, while among the control subjects only 36.5 % met at least one component. Additionally, we found that other factors not included among the operational definition of MetS, but still important in cardiovascular risk, were also altered. FEP patients have a greater risk of presenting at least one altered MetS component than healthy controls which could indicate the need of development of screening methods detecting cardiovascular risk. Likewise, gender differences in metabolic components such as waist circumference, which is a predictor of cardiovascular events have been found. Similarly, research should focus on metabolic risk predictors that include not only MetS, but also specific parameters for the early psychosis population.
YR 2022
FD 2022-07-22
LK http://hdl.handle.net/10668/22509
UL http://hdl.handle.net/10668/22509
LA en
DS RISalud
RD Apr 12, 2025